Modulation of the immune response to SARS-CoV-2 vaccination by NSAIDs .
Carsten SkarkeRonan LordanKayla BarekatAmruta NaikDivij MathewTakuya OhtaniAllison R GreenplateGregory R GrantNicholas F LahensSigrid GoumaElizabeth TroisiArjun SenguptaAalim M WeljieWenzhao MengEline T Luning PrakKendall LundgreenPaul BatesHu MengGarret A FitzGeraldPublished in: The Journal of pharmacology and experimental therapeutics (2023)
Evidence is scarce to guide the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to mitigate SARS-CoV-2 vaccine related adverse effects, given the possibility of blunting the desired immune response. In this pilot study, we deeply phenotyped a small number of volunteers who did or did not take NSAIDs concomitant with SARS-CoV-2 immunizations to seek initial information on the immune response. A SARS-CoV-2 vaccine specific RBD-IgG antibody response and efficacy in the evoked neutralization titers were evident irrespective of concomitant NSAID consumption. Given the sample size, only a large and consistent signal of immunomodulation would have been detectable, and this was not apparent. However, the information gathered may inform the design of a definitive clinical trial. Here, we report a series of divergent omics signals that invite additional hypotheses testing. Significance Statement A SARS-CoV-2 vaccine specific immune response was evident irrespective of concomitant NSAID consumption in a clinical pilot study of small sample size.